Xylem Inc. (NYSE:XYL) was downgraded by stock analysts at Boenning Scattergood from an “outperform” rating to a “neutral” rating in a note issued to investors on Monday.
Several other research analysts have also recently issued reports on the stock. Northcoast Research initiated coverage on shares of Xylem in a report on Thursday, November 17th. They issued a “buy” rating for the company. Janney Montgomery Scott upgraded shares of Xylem from a “neutral” rating to a “buy” rating and increased their price objective for the company from $50.00 to $52.00 in a report on Wednesday, November 2nd. RBC Capital Markets set a $51.00 price objective on shares of Xylem and gave the company a “buy” rating in a report on Tuesday, August 16th. Stifel Nicolaus increased their price objective on shares of Xylem from $47.00 to $48.00 and gave the company a “hold” rating in a report on Wednesday, November 2nd. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $58.00 price objective (up from $55.00) on shares of Xylem in a report on Monday, November 21st. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $47.15.
Xylem (NYSE:XYL) traded down 1.70% during mid-day trading on Monday, reaching $52.02. 514,426 shares of the company’s stock traded hands. Xylem has a 52-week low of $31.67 and a 52-week high of $54.99. The company has a market capitalization of $9.33 billion, a price-to-earnings ratio of 28.87 and a beta of 1.18. The company has a 50-day moving average of $50.29 and a 200-day moving average of $48.28.
Xylem (NYSE:XYL) last posted its earnings results on Tuesday, November 1st. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.53 by $0.01. Xylem had a net margin of 8.83% and a return on equity of 16.38%. The firm earned $897 million during the quarter, compared to analysts’ expectations of $913.53 million. During the same quarter in the prior year, the firm earned $0.49 EPS. Xylem’s quarterly revenue was down .6% on a year-over-year basis. Equities research analysts expect that Xylem will post $2.04 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 7th. Investors of record on Wednesday, November 9th will be given a $0.1549 dividend. The ex-dividend date is Monday, November 7th. This represents a $0.62 annualized dividend and a dividend yield of 1.17%. Xylem’s dividend payout ratio (DPR) is presently 34.44%.
In other Xylem news, insider Colin R. Sabol sold 27,473 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $50.91, for a total value of $1,398,650.43. Following the completion of the sale, the insider now owns 65,530 shares in the company, valued at approximately $3,336,132.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Claudia S. Toussaint sold 5,300 shares of the stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $47.27, for a total transaction of $250,531.00. Following the completion of the sale, the senior vice president now owns 44,033 shares of the company’s stock, valued at approximately $2,081,439.91. The disclosure for this sale can be found here. 0.77% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Advisor Group Inc. bought a new stake in Xylem during the second quarter worth about $100,000. Mizuho Asset Management Co. Ltd. increased its stake in Xylem by 122.1% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,323 shares of the company’s stock worth $104,000 after buying an additional 1,277 shares during the last quarter. IFP Advisors Inc increased its stake in Xylem by 113.6% in the second quarter. IFP Advisors Inc now owns 2,489 shares of the company’s stock worth $111,000 after buying an additional 1,324 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Xylem by 41.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,699 shares of the company’s stock worth $120,000 after buying an additional 788 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its stake in Xylem by 9.4% in the second quarter. Glenmede Trust Co. NA now owns 2,908 shares of the company’s stock worth $129,000 after buying an additional 250 shares during the last quarter. Institutional investors own 86.38% of the company’s stock.
Xylem Company Profile